| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 26, 2003
From the Departments of Pharmacology (J.A.A., E.J.C., J.L.S.) and Animal Biotechnology (G.A.-P., C.D.P., J.C., E.D.Z.), University of Nevada, Reno; Specialty Care (Cardiology), VA Salt Lake City Health Care System; and Departments of Internal Medicine (Cardiology) and Pharmacology, University of Utah School of Medicine, Salt Lake City (M.M.). * To whom correspondence should be addressed. E-mail: jaairey{at}med.unr.edu.
Background--We have investigated the usefulness of a model of cardiac development in a large mammal, sheep, for studies of engraftment of human stem cells in the heart. Methods and Results--Adult and fetal human mesenchymal stem cells were injected intraperitoneally into sheep fetuses in utero. Hearts at late fetal development were analyzed for engraftment of human cells. The majority of the engrafted cells of human origin formed segments of Purkinje fibers containing exclusively human cells. There were no differences in engraftment of human mesenchymal stem cells from adult bone marrow, fetal brain, and fetal liver. On average, 43.2% of the total Purkinje fibers in random areas (n=11) of both ventricles were of human origin. In contrast, Conclusions--Human mesenchymal stem cells preferentially engraft at high levels in the ventricular conduction system during fetal development in sheep. These findings raise the possibility that stem cells contribute to normal development of the fetal heart.
Revised on December 15, 2003
Accepted on December 23, 2003
Human Mesenchymal Stem Cells Form Purkinje Fibers in Fetal Sheep Heart
Judith A. Airey PhD*,
0.01% of cardiomyocytes were of human origin.
This article has been cited by other articles:
![]() |
H. Iwasaki, A. Kawamoto, C. Willwerth, M. Horii, A. Oyamada, H. Akimaru, T. Shibata, H. Hirai, S. Suehiro, S. Wnendt, et al. Therapeutic Potential of Unrestricted Somatic Stem Cells Isolated from Placental Cord Blood for Cardiac Repair Post Myocardial Infarction Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1830 - 1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-O. Kim, H. Tian, K. Prasongsukarn, J. Wu, D. Angoulvant, S. Wnendt, A. Muhs, D. Spitkovsky, and R.-K. Li Cell Transplantation Improves Ventricular Function After a Myocardial Infarction: A Preclinical Study of Human Unrestricted Somatic Stem Cells in a Porcine Model Circulation, August 30, 2005; 112(9_suppl): I-96 - I-104. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Haider and M. Ashraf Bone marrow stem cell transplantation for cardiac repair Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2557 - H2567. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kogler, S. Sensken, J. A. Airey, T. Trapp, M. Muschen, N. Feldhahn, S. Liedtke, R. V. Sorg, J. Fischer, C. Rosenbaum, et al. A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential J. Exp. Med., July 19, 2004; 200(2): 123 - 135. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |